Sandhya Mehla
Pain Medicine · West Hartford, CTNPI 1215356399
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,372 of the $11,908 with a category attached, or 61.9%. 22 manufacturers reported payments, led by Pfizer at 44.4% of the total. 2025 is the largest year on record at $5,468, more than ten times the $99 reported in 2019. Among pain medicine clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $40.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- AbbVie$4K
- Biohaven Pharmaceutical Holding Company Ltd.$580
- Teva Pharmaceuticals USA, Inc.$452
- Biohaven Pharmaceuticals, Inc.$445
- Lilly USA, LLC$257
- plus $990 from 16 others
What the payments were for
- Consulting fees$1,52513%
- Speaking & faculty fees$3,00025%
- Food & beverage$7,37262%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 35 | $5,291 |
| AbbVie(2 entities) | 176 | $3,893 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $580 |
| Teva Pharmaceuticals USA, Inc. | 18 | $452 |
| Biohaven Pharmaceuticals, Inc. | 9 | $445 |
| Lilly USA, LLC | 7 | $257 |
| Lundbeck LLC | 4 | $241 |
| Biogen | 5 | $127 |
| Scilex Pharmaceuticals Inc. | 6 | $126 |
| Amgen | 6 | $116 |
| Impel Pharmaceuticals Inc. | 1 | $83 |
| CSL Behring | 2 | $49 |
| Sanofi | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Argenx US, Inc. | 1 | $28 |
| Upsher-smith Laboratories LLC | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Collegium Pharmaceutical, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Amylyx Pharmaceuticals, Inc. | 1 | $19 |
| Kedrion Biopharma, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$4,887
- UBRELVY$217
- VYEPTI$131
How this compares
$11,908 in reported general payments places this provider in the 90th percentile of 69 pain medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 53 | $110,851 |
| UbrelvyUbrogepant | 46 | $54,451 |
| QuliptaAtogepant | 34 | $38,154 |
| Emgality PenGalcanezumab-Gnlm | 40 | $30,232 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $15,944 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 20 | $14,166 |
| Topiramate | 87 | $1,049 |
| Amitriptyline Hcl | 46 | $568 |
| Nortriptyline Hcl | 14 | $538 |
| Gabapentin | 61 | $402 |
| RizatriptanRizatriptan Benzoate | 23 | $358 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 33 | $292 |
| Tizanidine Hcl | 21 | $274 |
| ClopidogrelClopidogrel Bisulfate | 16 | $158 |
| Sumatriptan Succinate | 18 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $5,291 | $110,85153 claims |
| AbbVieUbrelvy, Qulipta | $3,893 | $92,60580 claims |
| Upsher-smith Laboratories LLCTopiramate | $26 | $1,04987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 pain medicine providers in Connecticut.
Other pain medicine in West Hartford
- Brian GrosbergWest Hartford$99K
- Sandeep JoharWaterbury$329K
- David GutierrezNew Haven$151K
- Ofer WellischStamford$18K
- Yili HuangNew Haven$18K
- Jared RosenbergGreenwich$12K
- Hans KnoppMiddlebury$11K
- Daniel HaddadNew Haven$10K
- Rahul AnandFairfield$9K
- Anthony KaramWestport$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.